$243 Million is the total value of NEXTHERA CAPITAL LP's 23 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 82.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Sell | SPDR S&P Biotech ETFput | $35,818,000 | -62.6% | 499,200 | -50.1% | 14.76% | -19.6% |
| IMMU | Sell | Immunomedics Inc | $12,767,000 | -56.2% | 894,679 | -36.0% | 5.26% | -5.7% |
| GBT | Sell | Global Blood Therapeutics Inc | $9,099,000 | -56.4% | 221,662 | -59.6% | 3.75% | -6.2% |
| EXEL | Sell | Exelixis Inc | $6,053,000 | -80.3% | 307,739 | -82.3% | 2.50% | -57.7% |
| CBAY | Sell | Cymabay Therapeutics Inc | $5,625,000 | -44.1% | 714,764 | -21.3% | 2.32% | +20.2% |
| CBIO | Sell | Catalyst Biosciences Inc | $2,967,000 | -69.2% | 376,010 | -57.9% | 1.22% | -33.7% |
| ZSAN | Sell | Zosano Pharma Corp | $1,693,000 | -60.0% | 798,719 | -22.7% | 0.70% | -13.8% |
| MDWD | Sell | MediWound Ltd | $424,000 | -60.2% | 104,546 | -39.6% | 0.18% | -14.2% |
| IMDZ | Exit | Immune Design Corp | $0 | – | -42,304 | -100.0% | -0.03% | – |
| AKRXQ | Exit | Akorn Inc | $0 | – | -35,000 | -100.0% | -0.09% | – |
| MTEM | Exit | Molecular Templates Inc | $0 | – | -105,600 | -100.0% | -0.11% | – |
| KERX | Exit | Keryx Biopharmaceuticals Inc | $0 | – | -200,000 | -100.0% | -0.13% | – |
| MDGL | Exit | Madrigal Pharmaceuticals Inc | $0 | – | -4,000 | -100.0% | -0.16% | – |
| ACAD | Exit | ACADIA Pharmaceuticals Inc | $0 | – | -43,980 | -100.0% | -0.18% | – |
| ACOR | Exit | Acorda Therapeutics Inc | $0 | – | -50,000 | -100.0% | -0.19% | – |
| ADAP | Exit | Adaptimmune Therapeutics Plcsponds adr | $0 | – | -74,132 | -100.0% | -0.19% | – |
| PRQR | Exit | ProQR Therapeutics NV | $0 | – | -52,875 | -100.0% | -0.20% | – |
| SVRA | Exit | Savara Inc | $0 | – | -97,600 | -100.0% | -0.21% | – |
| CLSD | Exit | Clearside Biomedical Inc | $0 | – | -181,011 | -100.0% | -0.21% | – |
| SGYPQ | Exit | Synergy Pharmaceuticals Inc | $0 | – | -746,200 | -100.0% | -0.24% | – |
| OMED | Exit | OncoMed Pharmaceuticals Inc | $0 | – | -634,715 | -100.0% | -0.26% | – |
| NEOS | Exit | Neos Therapeutics Inc | $0 | – | -311,502 | -100.0% | -0.29% | – |
| MGTA | Exit | Magenta Therapeutics Inc | $0 | – | -150,000 | -100.0% | -0.34% | – |
| ONCS | Exit | OncoSec Medical Inc | $0 | – | -1,388,824 | -100.0% | -0.37% | – |
| TGTX | Exit | TG Therapeutics Inc | $0 | – | -445,000 | -100.0% | -0.48% | – |
| SESN | Exit | Sesen Bio Inc | $0 | – | -1,177,000 | -100.0% | -0.48% | – |
| FGEN | Exit | FibroGen Inc | $0 | – | -50,414 | -100.0% | -0.59% | – |
| IOVA | Exit | Iovance Biotherapeutics Inc | $0 | – | -296,500 | -100.0% | -0.64% | – |
| FOMX | Exit | Foamix Pharmaceuticals Ltd | $0 | – | -747,308 | -100.0% | -0.82% | – |
| INSM | Exit | Insmed Incput | $0 | – | -250,000 | -100.0% | -0.97% | – |
| PFE | Exit | Pfizer Incput | $0 | – | -120,000 | -100.0% | -1.01% | – |
| LLY | Exit | Eli Lilly & Coput | $0 | – | -50,000 | -100.0% | -1.03% | – |
| KURA | Exit | Kura Oncology Inc | $0 | – | -311,536 | -100.0% | -1.04% | – |
| VKTX | Exit | Viking Therapeutics Inc | $0 | – | -327,730 | -100.0% | -1.09% | – |
| ACHN | Exit | Achillion Pharmaceuticals Inc | $0 | – | -1,583,954 | -100.0% | -1.12% | – |
| AZN | Exit | AstraZeneca PLCsponsored adr | $0 | – | -193,279 | -100.0% | -1.47% | – |
| NKTR | Exit | Nektar Therapeutics | $0 | – | -128,000 | -100.0% | -1.50% | – |
| TXMD | Exit | TherapeuticsMD Inc | $0 | – | -1,307,100 | -100.0% | -1.64% | – |
| ARQL | Exit | ArQule Inc | $0 | – | -1,737,397 | -100.0% | -1.88% | – |
| ACAD | Exit | ACADIA Pharmaceuticals Inccall | $0 | – | -500,000 | -100.0% | -1.99% | – |
| ABEO | Exit | Abeona Therapeutics Inc | $0 | – | -849,979 | -100.0% | -2.08% | – |
| ECYT | Exit | Endocyte Inc | $0 | – | -654,532 | -100.0% | -2.23% | – |
| CARA | Exit | Cara Therapeutics Inc | $0 | – | -737,303 | -100.0% | -3.38% | – |
| DOVA | Exit | Dova Pharmaceuticals Inc | $0 | – | -1,026,906 | -100.0% | -4.13% | – |
| MYL | Exit | Mylan NV | $0 | – | -695,788 | -100.0% | -4.88% | – |
| AGN | Exit | Allergan PLC | $0 | – | -158,712 | -100.0% | -5.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.